Among 28,000 isolates of the family Enterobacteriaceae and nonfermenters isolated at multiple medical centers, 1,084 (4%) were resistant to cefoperazone (MIC, .64 ,ug/ml) and 1,711 (6%) exhibited cefoperazone MICs of 2 to 32 ,ug/ml. Ninety-six percent of these 2,795 isolates produced j8-lactamase, as determined by the nitrocefin test. Sulbactam alone (8 ,ug/ml) was inactive against 99.6% of the isolates other than Acinetobacter calcoaceticus and Pseudomonas cepacia. Sulbactam enhanced the activity of cefoperazone against 56% of the isolates of the family Enterobacteriaceae and 44% of the nonfermenters. In the presence of sulbactam concentrations of c8 ,ug/ml, 65% of the cefoperazone-resistant isolates had reductions in cefoperazone MICs of .2 log2 dilution steps and were susceptible to c32 ,ug/ml. Antagonism was not observed.
tive and gram-negative organisms (4, 5, 9, 10, 14, (16) (17) (18) (19) , but its intrinsic antibacterial activity is limited.
In this study, investigators at medical centers in diverse geographic locations of the United States screened recent clinical isolates and determined their susceptibilities to cefoperazone and sulbactam, singly and in combination.
Laboratories from participating institutions isolated bacterial pathogens from clinical material and tested approximately 28,000 isolates of the family Enterobacteriaceae and nonfermenters for susceptibility to cefoperazone in vitro (12) . Each isolate was identified to the species level by standard methods (11) , and 1-lactamase production was determined by a rapid chromogenic cephalosporin (nitrocefin) test tration of sulbactam, and the effect of any given concentration of sulbactam varied with the bacterial species, as illustrated in Fig. 1 . Twenty-five of the cefoperazone-resistant isolates did not produce detectable P-lactamase, as follows: Acinetobacter calcoaceticus (n = 8); Escherichia coli (n = 4); Pseudomonas aeruginosa (n = 3); Xanthomonas maltophilia (n = 3); Citrobacterfreundii (n = 2); Providencia stuartii (n = 2); and Klebsiella pneumoniae, Klebsiella oxytoca, and Enterobacter cloacae (n = 1 each). Nevertheless, the combination exhibited enhanced activity for 12 of the 18 (67%) isolates in this subgroup that were not susceptible to sulbactam alone. Cefoperazone is very active against most strains of the family Enterobacteriaceae and Pseudomonas aeruginosa (1, 5, 6, 7, 15) ; median MICs are typically .1 and 4 to 8 ,ug/ml, respectively, and a susceptibility breakpoint of c32 ,ug/ml is generally accepted. Many bacterial species, those that are both susceptible and resistant to cefoperazone, produce P-lactamase enzymes (3-5, 8, 13, 15) . Although cefoperazone is vulnerable to the hydrolytic activity of some of these enzymes, they are only partially responsible for cefoperazone resistance (3, 13) , and other mechanisms may contribute to the resistance phenotype. The concomitant administration of a 13-lactamase inhibitor such as sulbactam would be expected to enhance the activity of cefoperazone against organisms if the following four conditions were present: (i) the organisms produced ,-lactamase, (ii) the enzyme hydro- Xanthomonas maltophilia, 37 isolates (h); Pseudomonas aeruginosa, 121 isolates (i); Klebsiella oxytoca, 41 isolates (j); and Acinetobacter calcoaceticus, 69 isolates (k). The cumulative percentage of cefoperazone-resistant Acinetobacter isolates inhibited by sulbactam alone is shown in panel 1. mechanism of resistance was due to P-lactamase production, and (iv) the inhibitor (sulbactam) inactivated the enzyme. The inhibitor could also enhance the activity of cefoperazone if it had significant intrinsic activity against the organisms, as is the case with Neisseria gonorrhoeae, Acinetobacter calcoaceticus, and Pseudomonas cepacia, or if it had a direct action (complementary to P-lactamase inhibition) on the penicillin-binding proteins of inhibitor-resistant organisms. In this study, the net effect of these various interactions on organisms from diverse geographic locations was determined with a large sample of isolates resistant to cefoperazone or for which cefoperazone MICs were 2 to 32 ,ug/ml; these isolates represented 4 and 6%, respectively, of all organisms screened. It is possible that the observed distribution of MICs might vary with the testing method. For example, if a broth macrodilution method had been used, the greater total number of organisms in a given inoculum would increase the chance of detecting an elevated MIC for a small portion of the population tested. Sulbactam-mediated enhancement of the activity of cefoperazone was observed more frequently against members of the family Enterobacteriaceae than against Pseudomonas species. It is likely that many of the former produced P-lactamase that was inhibited by sulbactam at the concentrations tested, whereas the latter did not. However, P-lactamase production, as measured by the nitrocefin test, was not a prerequisite for enhancement. The apparent synergistic effect of cefoperazone and sulbactam against Acinetobacter calcoaceticus and some strains of Pseudomonas cepacia, organisms which are typically more resistant to cefoperazone than members of the family Enterobacteriaceae and Pseudomonas aeruginosa are, was more likely due to the intrinsic activity of sulbactam than to P-lactamase inhibition.
In addition, sulbactam increased the observed activity of cefoperazone against some of the ,-lactamase-negative isolates, although it did not potentiate activity against all ,-lactamase-positive isolates. This suggests that alternate mechanisms, such as porin restrictions or alterations of the cefoperazone or sulbactam target(s), contribute to cefoperazone resistance in some organisms. The reduction in the MIC observed for the small number of cefoperazone-resistant, 3-lactamase-negative isolates may be the result of classical synergy of the two B-lactams or may reflect the limits of nitrocefin in detecting ,-lactamase(s). Induction of inapparent chromosomal ,B-lactamases was not attempted in this study.
The data presented here suggest that sulbactam increases the activity of cefoperazone against the Enterobacteriaceae and nonfermenters to various degrees in a species-and concentration-dependent manner and converts many cefoperazone-resistant strains into the susceptible range.
